Diabetic patients will particularly benefit from the wound healing capabilities of TheraSkin®. When conventional therapy fails, these patients are involved in nearly two-thirds of all non-traumatic lower limb amputations each year. TheraSkin® clinical results demonstrate the potential to heal wounds and save many patients from these life-threatening lower limb amputations by effectively closing wounds.
TheraSkin® is one of the fastest growing products in the advanced wound care market. The clinical outcomes and closure rates combined with cost effectiveness have been the drivers to growth. A retrospective study of 188 consecutive patients published in Foot & Ankle demonstrated healing speed in wounds from 1 to 252 cm2. DFU wounds in the group had 60.4% healing at 12 weeks and 74.1% at 20 weeks. The venous wounds group healed at 60.8% in 12 weeks and 74.6% at 20 weeks. The study demonstrated smaller VLU wounds of less than 6.34 cm2 had a healing rate of 86.67% in 20 weeks. (1).
TheraSkin® provides necessary growth factors and cytokines to treat chronic wounds; however, it also provides a large quantity of essential human collagens in appropriate ratios to support healing. This allows TheraSkin® to be used on more severe wounds with exposed bone, tendon, joint capsules or muscle.
About TheraSkin®: TheraSkin® is a biologically active cryo-preserved human skin allograft for non-responsive chronic wounds. It's fully developed extracellular matrix (ECM) and living cells provide an "at-ready" supply of human growth factors, cytokines and collagen to jumpstart wound healing. Like competing biologically active skin substitutes, TheraSkin® provides necessary growth factors and cytokines to treat chronic wounds; however, it also provides a large quantity of essential human collagens in appropriate ratios to support healing. This allows TheraSkin® to be used on more severe wounds with exposed bone, tendon, joint capsules or muscle.
Soluble Systems, LLC
11830 Canon Blvd., Suite A
Newport News, VA 23606
Telephone: (757) 877-8899
Toll-free: (877) 222-2681
Fax: (757) 877-8870
1) Landsman A.et al, Retrospective Study of 188 Consecutive Patients with a Biologically Active Human Skin Allograft (TheraSkin®) for Diabetic Foot and Venous Leg Ulcers, Foot & Ankle Specialist, Feb. 2011. Volume 4, no 1:29-41
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/florida-medicaid-now-covers-theraskin-300394255.html
SOURCE Soluble Systems, LLC